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A B S T R A C T
We assessed the relationship between anxiety and long-term metabolic control in adolescents with phenylk-
etonuria (PKU). We used a standardized psychological test to measure anxiety level and analyzed lifelong blood
phenylalanine stability in a selected group of 25 PKU teenagers with treatment adherence problems. We de-
monstrated significant correlations of anxiety with variability of blood phenylalanine concentrations and with
severity of hyperphenylalaninemia. Avoiding blood phenylalanine fluctuations in childhood can probably reduce
anxiety in PKU adolescents.
1. Introduction
Phenylketonuria (PKU; OMIM 261600) is one of the most common
inborn errors of metabolism and has become a classic example of a
treatable rare disease. A therapeutic diet with low content of pheny-
lalanine (Phe) should be implemented as soon as possible, ideally
within the first two weeks of life, to avoid serious brain damage and
intellectual disability in affected children [1]. The patients must adhere
to the dietary regimen for their entire lives.
Unfortunately, as in other chronic diseases, treatment adherence in
PKU decreases with time. This results in frequent occurrence of epi-
sodes of high blood Phe concentrations and it may lead to brain dys-
function presenting with neuropsychological deficits and behavioral
disturbances [2,3,4,5]. Although serious neuropsychological deficits
were frequently reported, especially in adolescents who abandoned
dietary treatment, little is known about the prevalence of the less tan-
gible, psychiatric complications such as anxiety and depression, which
may jeopardize the therapeutic goals. Previous reports have often been
based on clinical observations in adult patients [6,7], whereas the si-
tuation in adolescents is less clear.
In this study we focused on the measurement of anxiety levels in
teenagers with PKU using standardized psychological methods. Based
on published observations [8,9] and on our clinical experience with
patients from this age group, we hypothesized that anxiety can be re-
lated to instability of blood Phe concentrations.
2. Material and methods
We invited to our study all PKU teenagers aged 13–17 years, in
whom treatment was introduced no later than in the sixth week of life,
and who were subsequently continuously followed-up in our clinic. The
study entry criteria included also normal intellectual development,
treatment adherence problems (at least 25% of the results of control
blood Phe tests exceeding the recommended limit of 360 μmol/L), and
availability of genotyping results of the phenylalanine hydroxylase gene
(both disease-causing mutations identified). A group of 25 PKU patients
(18 girls and 7 boys) fulfilled the inclusion criteria and participated in
the study.
During a routine follow-up visit, every patient was assessed with use
of The State-Trait Anxiety Inventory (STAI), which is an introspective
psychological inventory consisting of 40 self-report items pertaining to
anxiety affect. The STAI distinguishes between a person's state and trait
anxiety levels. State anxiety (A-State) can be defined as fear, nervous-
ness and discomfort that are temporarily induced by situations per-
ceived as dangerous. Trait anxiety (A-Trait) can be defined as a rela-
tively enduring disposition to feel stress, worry and discomfort. Higher
STAI scores suggest higher anxiety [10].
Following psychological assessment, blood Phe concentration was
measured in every study participant.
In order to analyze the relationship of the STAI scores with dy-
namics of blood hyperphenylalaninemia we assessed a total of 4039
historical results of blood Phe tests, which were available in our clinic.
We considered two indicators of the severity of historical hyperphe-
nylalaninemia: the lifetime mean blood Phe concentration and the
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recent levels of hyperphenylalaninemia prior to psychological testing.
In addition, we analyzed lifetime standard deviation of blood Phe re-
sults, reflecting the metabolic stability in a given patient, and the fre-
quency of blood Phe measurements – an indicator of treatment ad-
herence.
The Pearson correlation statistics and multiple regression analysis
were used for data analysis. Benjamini-Hochberg FDR correction for
multiple comparisons was applied to confirm the statistical significance
of the observed correlations.
All procedures were in accordance with the 1964 Helsinki
Declaration and Good Clinical Practice guidelines. The regional ethics
committee approved the study. Informed consent was obtained from all
study participants.
3. Results
Table 1 presents demographic details, metabolic and psychological
data of the study participants.
The analysis of relationship of the STAI results with the severity of
hyperphenylalaninemia revealed moderate-to-strong correlations of
lifetime mean blood Phe concentrations and of recent blood Phe levels
with A-Trait scores (Pearson correlation coefficient r= 0.59 and 0.69,
corrected p= 0.005 and 0.0012, respectively). The assessment of re-
lationship between long-term stability of blood Phe, represented by the
SD values, and anxiety levels also resulted in detection of a statistically
significant correlation (r = 0.60; corrected p= 0.005). No statistically
significant findings were detected with regard to the mean frequency of
blood Phe measurements in relation with A-Trait scores (r = 0.31) as
well as for the A-State scores in relation to all analyzed metabolic
parameters.
Next, multiple regression analysis was performed to assess the
combined influence of recent blood Phe concentrations and of blood
Phe standard deviation values on the anxiety level. The model was
statistically significant (multiple R2 = 0.438, p = 0.0017) and revealed
stronger correlation of SD of blood Phe values with A-Trait scores
(standardized regression weight B = 0.503, p = 0.007) in comparison
with recent blood Phe concentrations (B = 0.294, p = 0.09).
4. Discussion
Only few interventional studies have assessed neuropsychiatric
symptoms that affect quality of life in PKU [6]. The assessed popula-
tions differed in regard to important aspects, such as treatment initia-
tion time, age, standards of PKU treatment (different recommendations
in various countries), and length of observation. We assessed a rela-
tively small but clinically homogenous group of continuously treated
teenagers, and we analyzed their entire treatment history.
The feeling of anxiety may develop in suddenly occurring stressful
situations or may be linked to longer-lasting psychological disorders.
The STAI allows for differentiation between both conditions. Our re-
sults suggest that A-Trait scores reflect the brain effects of hyperphe-
nylalaninemia better than A-State scores. This can probably be ex-
plained by relatively low dynamics of hyperphenylalaninemia in PKU
patients, who usually require several weeks to normalize high blood
Phe concentration. An increase of A-State score refers more to how a
person is feeling at the time of a perceived threat and is considered
temporary [10]. Based on our results it can be hypothesized that the
follow-up visit itself is not perceived by PKU teenagers as a big threat
even if they expect that their blood Phe levels exceed the recommended
limits.
Short-term increase in Phe concentrations limits the transport of
tyrosine and tryptophan across the blood-brain barrier [11], which in
turn directly affects the brain production of dopamine and serotonin
[12,13]. This can result in, at least partially reversible, neuropsycho-
logical abnormalities and decreased mood [3,4,5]. However, prolonged
hyperphenylalaninemia can additionally decrease cerebral protein
synthesis [14] and result in dysmyelination [15] with, potentially
permanent, serious brain damage [16,17]. Our findings suggest that
disposition to feel stress and worry in PKU teenagers can be a long-
lasting and hardly reversible phenomenon. It seems also that increased
anxiety level can result from hyperphenylalaninemia, which is in
agreement with previous observations [9], and from high changeability
of blood Phe concentration.
In conclusion, every effort should be made by physicians, psychol-
ogists and dieticians taking care of patients with PKU to avoid not only
hyperphenylalaninemia but also large fluctuations of blood Phe in af-
fected persons since early childhood. Continuous support to PKU fa-
milies and high-quality metabolic control in children can result in lower
frequency of anxiety, better quality of life and, possibly, better co-
operation with affected adolescents, who are going through their
teenage rebellion period.
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